NewYork‑Presbyterian and Catholic Health are partnering to bring Herbert Irving clinical trials to Long Island patients, with 20 studies already available.

Milan-based Bending Spoons priced 58M shares at $29 on Nasdaq, raising about $1.7B as the stock jumped and investors priced its plan to revive AOL, Vimeo and Eventbrite.

The FDA tapped seven companies — including Eli Lilly and Regeneron — for a PreCheck pilot to speed reviews of new U.S. drug plants. The cohort includes big pharma and specialized CDMOs.

The New York Times amended its June 25 complaint, dropping a claim against OpenAI and refocusing its allegations on Microsoft in a major copyright battle.

Mount Sinai scientists identified tiny blood particles called SECmeres that carry brain‑specific RNA and outperformed standard extracellular vesicles as potential Alzheimer’s biomarkers.

SpaceX has agreed to provide Reflection AI with GB300-class compute at its Colossus campus near Memphis in a deal that could reach $6.3 billion.

Pfizer announced that CFO Dave Denton will step down Aug. 15; Cecile Guegan will serve as interim CFO while the company launches a search for a successor. The move follows several major deals that reshaped Pfizer’s balance sheet.

A Rutgers genetic survey found many city mice carry mutations that blunt commonly used poisons, complicating pest control in Brooklyn.

A New York‑led coalition of state attorneys general served OpenAI with a sweeping subpoena seeking memos on advertising, retention, data and child and senior safety as the company confirms a confidential IPO filing.

Federal prosecutors say LangInnov settled after allegedly performing SBIR‑funded R&D overseas, a possible breach of NSF rules. The U.S. Attorney’s office framed the move as enforcement of domestic R&D requirements.

Long Island scientists are growing patient 'avatars' — organoids — to test dozens of drug combinations. Early trials show promise but wider validation and faster methods are still needed.

Albany approved S9051 this week to bar AI chatbot features that can harm or manipulate kids; the move was driven by parents testimony and advocacy groups.

Flourish surfaced from stealth with $500M and a $2.5B valuation, backed by Bezos and top VCs, promising a low‑power 'Cortex AI' that blends neuroscience and machine learning.